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Abstract
Background: Even though aberrant expression of microRNA (miR)-30d has been reported in prostate cancer (PCa),
its associations with cancer progression remain contradictory. The aim of this study was to investigate clinical
significance, biological functions and underlying mechanisms of miR-30d deregulation in PCa.
Methods: Involvement of miR-30d deregulation in malignant phenotypes of PCa was demonstrated by clinical
sample evaluation, and in vitro and in vivo experiments. The mechanisms underlying its regulatory effect on tumor
angiogenesis were determined.
Results: miR-30d over-expression was observed in both PCa cells and clinical specimens. High-miR-30d was
distinctly associated with high pre-operative PSA and Gleason score, advanced clinical and pathological stages,
positive metastasis and biochemical recurrence (BCR), and reduced overall survival of PCa patients. Through gain-
and loss-of-function experiments, we found that miR-30d promoted PCa cell proliferation, migration, invasion, and
capillary tube formation of endothelial cells, as well as in vivo tumor growth and angiogenesis in a mouse model.
Simulation of myosin phosphatase targeting subunit 1 (MYPT1), acting as a direct target of miR-30d, antagonized
the effects induced by miR-30d up-regulation in PCa cells. Notably, miR-30d/MYPT1 combination was identified as
an independent factor to predict BCR of PCa patients. Furthermore, miR-30d exerted its pro-angiogenesis function,
at least in part, by inhibiting MYPT1, which in turn, increased phosphorylation levels of c-JUN and activated VEGFA-
induced signaling cascade in endothelial cells.
Conclusions: miR-30d and/or its target gene MYPT1 may serve as novel prognostic markers of PCa. miR-30d
promotes tumor angiogenesis of PCa through MYPT1/c-JUN/VEGFA pathway.
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Background
As a unique and heterogeneous disease, prostate cancer
(PCa) represents the second most frequent malignancy in
men and a major cause of cancer-related deaths worldwide
[1]. The incidence and mortality of PCa are both rising
steadily in multiple countries. For example, approximately
220,000 American men were diagnosed as PCa and 27,000
died of this cancer in 2015 [2]. Although serum prostate-
specific antigen (PSA) has been extensively used as a diag-
nostic biomarker for clinical screening of patients with
PCa, the specificity of this parameter is relative low (about
25 ~ 40%) when it is between 4.0–10.0 ng/mL, leading to a
high rate of negative biopsy and overtreatment [3]. To over-
come this defect, accumulating studies have developed
multiple risk stratification systems, which integrate several
available clinical and pathological parameters (such as PSA
levels, Gleason score, and clinical and pathological stages)
[4]. Unfortunately, the efficiencies of these systems on early
diagnosis and outcome prediction are still unsatisfactory.
Therefore, there is an urgent clinical need to explore mo-
lecular mechanisms underlying tumor development and
progression of PCa, in order to identify novel biomarkers
which can distinguish indolent disease from aggressive dis-
ease, and to provide potential therapeutic targets for the
improvement of patients’ outcome.
MicroRNAs (miRNAs), a class of highly conserved,
small non-coding RNA molecules with 18–25 nucleo-
tides in length, function as post-transcriptional regula-
tors of gene expression via directly degrading mRNA or
indirectly repressing protein translation [5]. Growing
evidence show that miRNA deregulation is implicated
into multiple human cancers through regulating a wide
range of pathological processes [6]. Functionally, miR-
NAs act as either oncogenes or as tumor suppressors
due to the different cellular contexts of malignancies [7].
miR-30d, together with miR-30a, b, c and e, belongs to
the human miR-30 family and is localized to chromo-
somal region 8q24 [8]. Accumulating studies have re-
vealed that miR-30d plays a crucial role in various
physiological processes in normal and malignant tissues,
including cell development, proliferation, apoptosis, mi-
gration, invasion and angiogenesis [9, 10].
There are still controversies about the roles of miR-
30d in human PCa. A previous study of Kobayashi et
al. [11] showed that miR-30d might serve as a poten-
tial unfavorable prognostic factor in PCa; Liang et al.
[12] indicated that miR-30d expression was up-
regulated in high Gleason score (≥8) PCa; In contrast,
Xuan et al. [13] reported that it exhibited tumor sup-
pressive properties in this cancer; Xu et al. [14] ob-
served the downregulation of miR-30d in PCa; Kumar
et al. [15] indicated that miR-30d levels in metastatic
castration resistant PCa (CRPC) were significantly re-
duced when compared to healthy prostate tissues, and
were inversely correlated with AR activity. These dif-
ferent findings might be caused by patients’ heteroge-
nicity and various experimental platforms. To
determine the exact role of miR-30d in PCa, we here
examined the expression patterns of miR-30d in PCa
cell lines and clinical tissue samples, and then verified
its clinical relevance and functions on various malig-
nant phenotypes of PCa cells using both gain- and
loss-of-function analyses. Moreover, we identified
direct target genes of this miRNA and further investi-
gated the molecular mechanisms underlying the pro-




This study was approved by the human study ethics
(IRB) committees at MGH, Boston, MA and the Minis-
try of Public Health of P. R. China. All specimens were
handled and made anonymous according to the ethical
and legal standards.
All animal experiments in this study were performed
in compliance with the guidelines of the Institute for
Laboratory Animal Research at Guangzhou Medical
University, Guangzhou, P. R. China.
Patients and tissue samples
This study used the same cohorts of patients and tissue
samples with our previous study [16]. Detailed informa-
tion is provided in Additional file 2: File S1-section 1.
Cell culture
Normal human prostate epithelial cells (PREC) and
two human PCa cell lines LNCaP and DU145 were
used in this study. Detailed information is provided in
Additional file 2: File S1-section 2.
Animals
Twenty BALB/c nude mice (4 ~ 5-week-old males) were
purchased from Guangdong Medical Laboratory Animal
Center and were housed five per cage in wire-top cages
with sawdust bedding in an isolated, clean, air-
conditioned room at a temperature of 25–26 °C and a
relative humidity of ~50%, lit 12 h/day.
Cell transfection
To enforce and inhibit the expression of miR-30d in
PCa cells, the miR-30d precursor and sh-miR-30d
construct were respectively transfected according to
the protocol described previously [16–18]. For the
miR-30d precursor (miR-30d), the coding sequence of
miR-30d was cloned into the pMIRNA1 lentivectors
(Human pre-microRNA Expression Construct Lenti-
miR-30d MI0000255, Cat No: PMIRH30dPA-1, SBI,
Lin et al. Molecular Cancer  (2017) 16:48 Page 2 of 14
USA; The coding sequence of miR-30d is provided in
Additional file 2: File S1-section 3); For negative con-
trol precursor (miR-NC), pCDH-CMV-Scramble
hairpin-EF1-copGFP (CD511B-1) was purchased from
the same vendor (Cat No: PMIRH000PA-1, SBI, USA);
For sh-miR-30d (sh-30d) and anti-control (sh-NC)
constructs, the miRZip-30d sh-miR-30d microRNA
construct (Cat No: MZIP30d-PA-1) and miRZip con-
trol vectors (Cat No: MZIP000-PA-1) were designed
and cloned by SBI, USA. To package these constructs,
293TN cells were transfected with miR-30d/miR-NC
or sh-30d/sh-NC by pPACKH1 Packaging Plasmid
Mix (Cat No: LV500A-1, SBI, USA), and then after
three days, the virus particles were collected according
to the packaging protocol of SBI with the Lenti-
Concentin Virus Precipitation Solution (Cat No:
LV810A-1, SBI, USA). DU145 and LNCaP cells were
infected with TransDux virus transduction reagent
(Cat No: LV850A-1, SBI, USA). The infected cells were
isolated with a flow cytometer and cultured in 96-well
plates.
The myosin phosphatase targeting protein 1
(MYPT1) coding sequence cloned into pLL3.7-CMV-
IRES-puro-Vector (Provided by Huijun company of
China)/blank vector (NC), and shRNA-targeting hu-
man MYPT1 (sh-MYPT1, Cat. No: GV248, Genechem,
China) and the shRNA non-targeting (sh-NC, Cat. No:
CON077, Genechem, China) were transfected into
PCa cells using Lipofectamine 2000 Reagent (Cat. No:
11668019, Invitrogen, USA) according to the manufac-
turer’s protocol. Forty-eight hours after the transfec-
tion, PCa cells were collected and used for the
functional analyses.
Cell viability assay
Cell viabilities were detected by CCK-8 assay according
to the protocol of our previous studies [16–18].
Cell invasion and migration assays
Cell invasion and migration were respectively detected
by the Transwell and the scratch wound-healing mo-
tility assay according to the protocol of our previous
studies [16–18].
Tube formation
HUVECs (2 × 104) were plated onto matrigel-coated
(10 mg/ml, BD Pharmingen, San Jose, CA) 12-well
plates with condition media of LNCaP and DU145 cells.
After 12 hours of the incubation at 37 °C, HUVECs
were fixed with 4% paraformaldehyde and the forma-
tion of capillary-like structures was captured under a
light microscope (OLYMPUS CKX41, U-CTR30-2,
Japan). The number of branch points of the tube
structures, as the degree of angiogenesis, was counted
in three fields at 100× magnification.
In vivo tumor angiogenesis assay
For the in vivo tumor formation and angiogenesis assays,
the xenograft model of PCa was established according to
our previous descriptions (Additional file 2: S1-section
4) [16–18]. Five weeks later for miR-30d and miR-NC
PCa cells while seven weeks later for sh-30d and sh-NC,
tumors were removed, fixed in formalin, and embedded
in paraffin. Expression patterns of vascular endothelial
growth factor A (VEGFA) and CD31 proteins in differ-
ent groups were respectively detected by Western blot
analysis and immunohistochemistry. The microvessel
density (MVD) in tumor tissues was evaluated based on
the immunostaining for CD31.
Gene expression profiling
To identify the differentially expressed genes (DEGs) in
LNCaP and DU145 cells transfected with miR-30d/miR-
NC vectors, total RNA were amplified, labeled and puri-
fied by using GeneChip 3’IVT Express Kit (Cat#901229,
Affymetrix, Santa Clara, CA, US) followed the manufac-
turer’s instructions to obtain biotin labeled cRNA. Array
hybridization and wash was performed using GeneChip®
Hybridization, Wash and Stain Kit (Cat#900720, Affyme-
trix, Santa Clara, CA, US) in Hybridization Oven 645
(Cat#00-0331-220 V, Affymetrix, Santa Clara, CA, US)
and Fluidics Station 450 (Cat#00-0079, Affymetrix, Santa
Clara, CA, US) followed the manufacturer’s instructions.
Slides were scanned by GeneChip® Scanner 3000 (Cat#00-
00212, Affymetrix, Santa Clara, CA, US) and Command
Console Software 3.1 (Affymetrix, Santa Clara, CA, US)
with default settings. Raw data were normalized by MAS
5.0 algorithm, Gene Spring Software 11.0 (Agilent tech-
nologies, Santa Clara, CA, US). The microarray data (ID:
GSE85884) were deposited in Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/). Then, signifi-
cant DEGs were identified between the test and control
groups using the criteria of P value <0.05 and |log2 fold
change (FC)| > 0.5 with the R package (version 1.0.2, R
Core Team, Vienna, Austria).
Prediction of target genes of miR-30d
Three online programs Target-Scan (release 6.2) [19],
miRWalk (Last Update: March 29, 2011) [20], and mi-
Randa (August 2010 Release, Last Update: November
01, 2010) [21] were used to predict potential target genes
for miR-30d.
Luciferase reporter assay
To verify the binding site of miR-30d and its candi-
date target gene MYPT1, the luciferase reporter assay
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was performed according to our previous descriptions
(Additional file 2: File S1-section 5) [16–18].
qRT-PCR
Expression levels of miR-30d, CALD1, TNPO1, ATP2B1,
SEPT7, MYPT1, ZNF148, CEP350, KIF5B, STAG2 and
GALNT1 mRNA in PCa cell lines and clinical PCa tis-
sues were detected by qRT-PCR analysis according to
our previous descriptions [16–18]. The sequences of all
the primers are provided in Additional file 3: Table S1.
Western blot analysis
Expression levels of MYPT1, total-c-JUN, p-c-JUN
(ser63), p-c-JUN (ser73) and VEGFA proteins in PCa cell
lines and clinical PCa tissues were detected by Western
blot analysis according to the protocol of our previous
studies [16–18]. The antibodies are provided in Additional
file 3: Table S2.
Immunohistochemistry
Cellular distribution and expression level of MYPT1
protein in clinical PCa tissues, and those of CD31 pro-
tein in subcutaneous tumor xenografts of nude mice
were examined by immunohistochemistry according to
our previous description [16–18]. The antibodies used in
this study were shown in Additional file 3: Table S2.
Statistical analyses
All statistical analyses were performed by SPSS software
for Windows (version 17.0, SPSS Inc, IL, USA). Data of
continuous variables were expressed as mean ± S.D. Data
obtained from qRT-PCR and Western blot were con-
ducted using Wilcoxon signed-rank test. Associations of
miR-30d/MYPT1 expression with various clinicopatho-
logical parameters were evaluated by Fisher’s exact test
for any 2 × 2 tables and Pearson χ2 test for non-2 × 2 ta-
bles. Survival analysis was performed by Kaplan-Meier
method and Cox regression model. Correlation between
miR-30d and MYPT1 expression in clinical PCa tissue
samples was assessed by the Spearman correlation ana-
lysis. For functional analyses in vitro and in vivo, the dif-
ferences between groups were analyzed using a Student
t test when comparing only two groups or one-way ana-
lysis of variance when comparing more than two groups.
Differences were considered statistically significant when
the P value was less than 0.05.
Results
miR-30d over-expression associates with advanced pro-
gression and unfavorable prognosis in human PCa
Compared to adjacent non-cancerous prostate tissues
and normal human prostate epithelial cells, the expres-
sion levels of miR-30d were respectively increased in
PCa tissues and two PCa cell lines (all P < 0.05, Add-
itional file 1: Figure S2).
Associations of miR-30d expression with various
clinicopathological parameters and patients’ prognosis
of PCa were evaluated based on publicly available
Taylor and TCGA datasets. PCa patients with high
pre-operative PSA (for Taylor: P = 0.003) and Gleason
score (for Taylor and TCGA: P = 0.010 and 0.001, re-
spectively), advanced clinical (for Taylor: P = 0.007)
and pathological stages (for Taylor: P = 0.004), and
positive metastasis (for Taylor: P = 0.001) and bio-
chemical recurrence (BCR, for Taylor and TCGA: P =
0.002 and 0.037, respectively) more frequently had
higher expression level of miR-30d than those in the
corresponding control groups (Additional file 3: Table
S3). In survival analysis based on the Taylor dataset,
all 113 PCa patients were divided into two groups
(miR-30d-low, n = 57; miR-30d-high, n = 56) by setting
cut-off value at the median miR-30d expression level.
Then, pairwise comparisons showed significant differ-
ences in the BCR-free survival (P = 0.001, Fig. 1a) and
overall survival (P = 0.041, Fig. 1a) between patients
with high and low miR-30d expressions. Further uni-
variate analysis using a COX regression model re-
vealed that miR-30d expression was significantly
correlated with BCR-free survival of PCa patients
(Additional file 3: Table S4). Although the PCa pa-
tients in high miR-30d expression group had a trend
of short BCR-free survival based on TCGA dataset,
there was no statistical significance, due to a relative
small BCR positive cohort in this dataset (Fig. 1a).
miR-30d promotes tumor growth and angiogenesis in
vivo
To further determine the roles of miR-30d in tumor
growth and angiogenesis in vivo, LNCaP and DU145 PCa
cell lines stably expressing miR-30d or control vector were
subcutaneously implanted into nude mice. LNCaP (Fig. 1b)
and DU145 (Additional file 1: Figure S3A and B) cells sta-
bly expressing miR-30d formed significantly larger tumor
nodules and remarkably speeded up tumor xenografts
growth compared with the controls. Conversely, PCa cells
that permanently suppressed miR-30d expression led to
the smaller tumor nodules and the slower tumor growth
compared with the controls (for LNCap: Fig. 1b; for
DU145: Additional file 1: Figure S3 A and B).
Moreover, immunohistochemical analysis using pan-
endothelial marker CD31 antibody were employed to
evaluate the angiogenesis of the tumor xenografts. As
a result, the immunostaining of CD31 protein in the
tumor xenografts established by LNCaP (Fig. 1c) or
DU145 (Additional file 1: Figure S3C) cells stably ex-
pressing miR-30d were remarkably stronger than that
in the control group. Contrarily, the tumor xenografts
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established by sh-30d-transfected LNCaP (Fig. 1c) or
DU145 (Additional file 1: Figure S3C) cells presented
markedly weaker CD31 immunostaining than the con-
trol xenografts. Consistently, the microvessel density
(MVD) levels in tumor tissues of the subcutaneous
models bearing miR-30d- and sh-miR-30d-transfected
PCa cells were significantly higher and lower than
those of the respective controls (both P < 0.05, Fig. 1c
and Additional file 1: Figure S3C), which were in line
with the changes into VEGFA protein expression in
different groups (both P < 0.05, Fig. 1d and Additional
file 1: Figure S3D).
miR-30d enhances the promoting effects of PCa cells on
in vitro proliferation, migration, invasion, and increases
the abilities of PCa cells to recruit endothelial cells
QRT-PCR analysis confirmed that the expression levels
of miR-30d in LNCaP cells transfected with a lentiviral
vector expressing miR-30d and sh-30d were respectively
higher and lower than those with miR-NC and sh-NC
vectors (Additional file 1: Figure S4A), which were simi-
lar with the findings of DU145 cells (Additional file 1:
Figure S5A).
CCK-8 assays indicated that the cellular proliferation of
miR-30d-introduced LNCaP (Additional file 1: Figure S4B)
Fig. 1 Prognostic value of miR-30d expression in PCa patients and its functions on tumor growth and angiogenesis in vivo using LNCaP cell in-
duced tumor xenografts. a Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival and overall survival of PCa patients based on miR-
30d expression in Taylor and TCGA datasets. b LNCaP cells stably expressing miR-30d formed significantly larger tumor nodules and remarkably
speeded up tumor xenografts growth compared with the controls. Conversely, PCa cells that permanently suppressed miR-30d expression led to
the smaller tumor nodules and the slower tumor growth compared with the control. c Immunohistochemical analysis using pan-endothelial
marker CD31 antibody. d VEGFA protein expression in different groups detected by Western blot analysis. Data were presented as Mean ± SD.
*P < 0.05. **P < 0.01
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and DU145 cells (Additional file 1: Figure S5B) were both
significantly higher than those of control vectors-
transfected cells (all P < 0.05), while the knockdown of
miR-30d expression dramatically decreased the cell viability
(all P < 0.05, Additional file 1: Figure S4B and S5B).
Transwell assays clearly revealed that enforced expres-
sion of miR-30d significantly enhanced the invasive ac-
tivities of both LNCaP (Additional file 1: Figure S4C)
and DU145 (Additional file 1: Figure S5C) cells, which
were reduced by loss of miR-30d distinctly (Additional
file 1: Figure S4C and S5C, all P < 0.05).
Wound-healing assays demonstrated that miR-30d up-
regulation markedly strengthened the migratory abilities
of both LNCaP (Additional file 1: Figure S4D) and
DU145 (Additional file 1: Figure S5D) cells, which were
also suppressed by the transfection of sh-miR-30d vector
(Additional file 1: Figures S4E and S5E, all P < 0.05).
To assess the influence of miR-30d in the abilities
of PCa cells to recruit endothelial cells, the condition
medium of the PCa cells was collected and the trans-
well, wound healing and tube formation assays were
performed. As a result, the culture medium of miR-
30-transfected LNCaP (Fig. 2) and DU145 (Additional
file 1: Figure S6) cells significantly enhanced the inva-
sive and migrated abilities of HUVECs, and also pro-
moted their capillary tube formation. In contrast, the
medium of sh-miR-30d-transfected LNCaP (Fig. 2)
and DU145 (Additional file 1: Figure S6) cells induced
obvious decreases in the abilities of HUVEC invasion,
migration and capillary tube formation.
MYPT1 is a direct target of miR-30d
Gene expression profiles of miR-30d- and miR-NC-
transfected LNCaP and DU145 cells were respectively
detected and normalized. With the thresholds of P
value <0.05 and |log2 FC| >0.5, a total of 146 DEGs
were commonly identified in both LNCaP and DU145
cells, including three up-regulated DEGs and 143
down-regulated DEGs (Additional file 3: Table S5).
Then, three miRNA target predicting programs (Target-
Scan, miRWalk, and miRanda) were used to identify the
putative targets of miR-30d, and found that there were 36
putative targets of miR-30d which were also downregu-
lated in both miR-30d-transfected LNCaP and DU145
cells according to the gene microarray analysis (Additional
file 3: Table S6 and Fig. 3a).
After the pathway enrichment analysis based on KEGG
database, we found that the above 36 putative targets of
miR-30d were significantly associated with several tumor-
related pathways, such as RhoA signaling, DNA methyla-
tion and transcriptional repression signaling, Signaling by
Rho family GTPases and PI3K/AKT signaling (Additional
file 3: Table S7 and Additional file 1: Figure S7), which all
have broad effects on cell behavior.
Fig. 2 miR-30d enhances the capillary tube formation of endothelial cells. a Transwell assays of the invasive abilities of HUVECs with the culture
medium of miR-30 or sh-miR-30d-transfected LNCaP cells; b Wound-healing assays of the migrated abilities of HUVECs with the culture medium
of miR-30 or sh-miR-30d-transfected LNCaP cells; c Capillary tube formation assays of HUVECs with the culture medium of miR-30 or sh-miR-30d-
transfected LNCaP cells. Data were presented as Mean ± SD. *P < 0.05. **P < 0.01
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In addition, qRT-PCR analysis was performed and the
results showed that the endogenous expression levels of
SEPT7, MYPT1, ZNF148, CEP350, STAG2 and GALNT1
in miR-30d-transfected LNCaP (Fig. 3b) and DU145
(Additional file 1: Figure S8A) cells were all significantly
reduced at mRNA levels (P < 0.05). Among them, only
MYPT1 is a major component in RhoA signaling pathway,
which was one of the significantly enriched pathways in-
volved by miR-30d-induced differentially-expressed pro-
teins. Accumulating studies have reported that RhoA
signaling pathway plays an important role in tumorigen-
esis and cancer metastasis [22]. Thus, MYPT1 would be
selected as a candidate target for further analyses.
To confirm MYPT1 being targeted by miR-30d, the lucif-
erase reporter containing the complimentary seed sequence
of miR-30d at the 3’-UTR regions of MYPT1 mRNA was
constructed. Luciferase activity assays showed that the
expression of the MYPT1 reporter was significantly re-
duced by co-transfection with has-miR-30d mimics. In con-
trast, the expression of the MYPT1 reporter containing the
mutated sequence of the same fragment was not affected
by co-transfection with hsa-miR-30d mimics (Fig. 3c). The
results indicated that the fragment at the 3'-UTR of
MYPT1 mRNA was the complementary site for the miR-
30d seed region, suggesting that MYPT1 may be a direct
target of miR-30d.
MYPT1 functions as a critical downstream mediator of
miR-30d's oncogenic effects in PCa progression
We performed western blot to detect the expression
levels of MYPT1 protein in LNCaP and DU145 cells
transfected by lentivectors and in the tumor xeno-
grafts established by these PCa cells. MYPT1 protein
levels were remarkably down-regulated in LNCaP
Fig. 3 MYPT1 functions as a critical downstream mediator of miR-30d's oncogenic effects in PCa progression. a Intersections among gene micro-
array identification and bioinformatics miRNA target prediction algorithm. b QRT-PCR analysis was performed detect the endogenous expression
levels of SEPT7, MYPT1, ZNF148, CEP350, STAG2 and GALNT1 in miR-30d-transfected LNCaP cells. c Luciferase activity assays was performed to
confirm the direct binding efficiency of miR-30d and its putative target MYPT1; d Western blot analysis was performed to detect the expression
levels of MYPT1 protein in LNCaP cells transfected by lentivectors and in the tumor xenografts established by these LNCaP cells; e ~ h MYPT1
simulation antagonized the increasing effects on the abilities of migration, invasion, and capillary tube formation of HUVECs induced by miR-30d
up-regulation in LNCaP cells. Data were presented as Mean ± SD. *P < 0.05. **P < 0.01
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(Fig. 3d) or DU145 (Additional file 1: Figure S8B) cells
stably overexpressing miR-30d. The similar findings
were observed in the corresponding tumor xenografts
established by cell lines overexpressing miR-30d
(Fig. 3d and Additional file 1: Figure S8B). In contrast,
the expression levels of MYPT1 protein in sh-miR-
30d-transfected cell lines and the corresponding
tumor xenografts were all significantly up-regulated
(Fig. 3d and Additional file 1: Figure S8B). Overall,
miR-30d negatively regulated MYPT1 expression in
vitro and in vivo.
To clarify whether the roles of miR-30d in PCa
were mediated through suppressing MYPT1 expres-
sion, pCDNA3.1(+)-Vectors expressing MYPT1 were
conducted. As shown in the Fig. 3e ~ h, Additional
file 1: Figure S8C ~ D and Figure S9, MYPT1 simula-
tion antagonized the increasing effects on the abilities
of migration, invasion, and capillary tube formation of
HUVECs induced by miR-30d up-regulation in PCa
cells.
miR-30d/MYPT1 combination is a more efficient
prognostic factor for BCR-free survival of PCa patients
than miR-30d or MYPT1 alone
On the basis of our clinical cohort of PCa sample tis-
sues, the Taylor and TCGA datasets, the Spearman Cor-
relation analysis clearly presented a negative correlation
between MYPT1 mRNA and miR-30d expression in PCa
tissues (for our clinical cohort: Fig. 4a, for Taylor and
TCGA datasets: Additional file 1: Figure S10).
To investigate whether MYPT1 expression could be
linked to the clinicopathological features of human PCa,
the immunohistochemical staining was employed to de-
tect the expression pattern and subcellular localization
of MYPT1 expression in 225 PCa and 25 adjacent non-
cancerous prostate tissues. As shown in Fig. 4b, the anti-
body that specifically recognizes MYPT1 stained the
cytoplasm and cellular membrane of PCa cells, and gave
evenly distributed staining pattern with various inten-
sities. The immunoreactive scores (IRS) of MYPT1 pro-
tein in PCa clinical samples was significantly lower than
that in adjacent benign tissues (P < 0.001, Fig. 4c). Inter-
estingly, MYPT1 protein expression in PCa tissues dis-
played a decreasing trend depend on the increasing
Gleason scores (P < 0.05, Fig. 4c) and the presence of
BCR (P < 0.05, Fig. 4c).
Then, the data shown in Additional file 3: Table S8 re-
vealed that low IRS of MYPT1 protein was significantly
associated with high Gleason score (P = 0.002), positive
metastasis (P = 0.018) and BCR (P < 0.001) and shorter
overall survival (P = 0.005) of PCa patients. Kaplan-
Meier analysis showed that there were significant differ-
ences in the BCR-free survival (P < 0.001, Fig. 4d),
overall survival (P = 0.005, Fig. 4d) and metastasis-free
survival (P = 0.005, Fig. 4d), between patients with high
and low MYPT1 expression. Notably, regarding to the
PCa patients with Gleason score = 7, low MYPT1 ex-
pression was significantly associated with short BCR-free
survival (P = 0.037, Fig. 4e). In addition, the prognostic
potential of miR-30d/MYPT1 combination in BCR-free
survival of PCa patients was also confirmed using the
Taylor dataset (P = 0.003, Fig. 4f ). Further Cox propor-
tional hazards multivariate model revealed that the pre-
diction efficiency of miR-30d/MYPT1 combination to
BCR of PCa patients was stronger than the two markers’
alone (For prognostic implication of MYPT1 based on
its immunostainings using human PCa tissue microar-
rays: Table 1; For prognostic implications of miR-30d
and/or MYPT1 based on the Taylor dataset: Additional
file 3: Table S9, P value of miR-30d/MYPT1 combination
for BCR-free survival vs. P values of miR-30d or MYPT1:
0.026 vs. 0.027 or 0.624).
miR-30d promotes angiogenesis via MYPT1/c-JUN/VEGFA
pathway in PCa
The above data indicated an important role of miR-30d/
MYPT1 axis in tumor angiogenesis of PCa in vitro and in
vivo, which prompted us to investigate the underlying mo-
lecular mechanisms. As a potent endothelial mitogen,
VEGFA has been demonstrated to be crucial for cancer
growth and neovascularization [23]. Our data mentioned
above showed that miR-30d up-regulation could increase
the expression level of VEGFA protein in PCa cell lines and
in tumor tissues of the subcutaneous models. The VEGFA
promoter region includes several candidate binding sites
for the transcription factors, such as hypoxia inducible
factor-1α (HIF-1α), activator protein-1 (AP-1, c-JUN), AP-2
and Specificity protein-1 (SP-1) [24]. Thus, we firstly trans-
fected si-HIF-1α, si-c-JUN, si-AP-2 and si-SP-1 into LNCap
and DU145 cells, and found that the loss of HIF-1α, AP-2
and c-JUN transcription activities significantly inhibited the
expression level of VEGFA protein (Fig.5a and Additional
file 1: Figure S11A). Since MYPT1 functions as targeting
and regulatory subunits to confer substrate specificity and
subcellular localization on the catalytic subunit of type 1d
protein serine/threonine phosphatase [25], we hypothesized
that the pro-angiogenic role of miR-30d might be related to
the effect of MYPT1 on the activation of c-JUN and the ex-
pression of VEGFA. To verify this hypothesis, western blot
analysis was performed to detect the expression levels of
total-c-JUN, p-c-JUN (ser63), p-c-JUN (ser73) and VEGFA
proteins in LNCap and DU145 cells transfected with miR-
30d expressing or si-MYPT1 vectors. As shown in Fig.5b ~
f and Additional file 1: Figure S11B ~ F, both the enforced
expression of miR-30d and the knockdown of MYPT1 sig-
nificantly activated c-JUN and increased the expression of
VEGFA protein, implying that c-JUN and VEGFA might
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function as the downstream effectors of miR-30d-MYPT1
axis in human PCa cells and be implicated in tumor angio-
genesis during PCa progression.
Discussion
Growing evidence show that active angiogenesis, a
critical step in cancer development and progression, is
responsible for the rapid recurrence and poor progno-
sis of patients with PCa [26]. Dysfunction of miRNAs
in malignant cells has been revealed to play important
roles in tumor angiogenesis [27, 28]. In the current
study, we identified the pro-angiogenic function of
miR-30d in PCa for the first time using in vitro and
in vivo assays. The elevated level of miR-30d expres-
sion was positively associated with aggressive progres-
sion and short BCR-survival of patients with PCa.
Through up- and down-regulating miR-30d in PCa
cells, we confirmed that miR-30d could efficiently en-
hance the abilities of in vitro proliferation, migration,
invasion and capillary tube formation of HUVECs, as
well as promote in vivo tumor growth and angiogen-
esis in nude mice models bearing human PCa. We also
found that the pro-angiogenic effect of miR-30d might
be due to its regulation on the direct target gene
MYPT1, subsequently leading to the activation of c-
JUN and the increased expression of VEGFA protein,
Fig. 4 miR-30d/MYPT1 combination is a more efficient prognostic factor for BCR-free survival of PCa patients than miR-30d or MYPT1 alone. a
Correlation between MYPT1 mRNA and miR-30d expression in PCa tissues was evaluated by Spearman Correlation analysis; b Immunohistochemi-
cal staining images of MYPT1 protein in adjacent non-cancerous prostate tissues and PCa tissues with different Gleason scores; c The immunore-
active scores (IRS) of MYPT1 protein in PCa clinical samples and adjacent benign tissues; d and e Kaplan-Meier analysis on the associations
between MYPT1 expression and BCR-free survival, overall survival and metastasis-free survival; f Kaplan-Meier analysis on the associations between
miR-30d/MYPT1 combination and BCR-free survival and overall survival of PCa patients using the Taylor dataset
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a critical pro-angiogenic factor secreted by cancer
cells.
The miR-30 family of miRNAs is involved in regulation
of various physiological processes in normal and malig-
nant tissues, such as epithelial-mesenchymal transition
(EMT), which is a developmental program characterized
by loss of cell adhesion and increased cell mobility, and is
critical for embryogenesis and organ development [29].
Dysregulation of the miR-30 family members are found
implicated in tumor development and progression; how-
ever, inconsistency exists about their function in various
cancer types. For example, they have been identified as
oncomiRNAs melanoma (miR-30b/d) [10], renal cancer
(miR-30c) [30], hepatocellular carcinoma (miR-30d) [31],
and glioma (miR-30e) [32]; In contrast, they function as
tumor suppressors in breast cancer (miR-30a) [33], non-
small cell lung cancer (miR-30b/miR-30c) [34], renal
carcinoma (miR-30d) [35], and gastrointestinal cancer
(miR-30c) [36]. As a member of this family, miR-30d has
been identified as a novel cancer-related biomarker and a
potential therapeutic target in multiple malignancies. It
functions either as an oncomiR or a tumor suppressor de-
pend on cancer types through regulating different target
genes. The decreased expression of miR-30d was observed
in chronic lymphocytic leukemia [37], thyroid cancer [38],
renal carcinoma [35] and cervical cancer [39], and was as-
sociated with highly malignant phenotypes of these cancer
cells; Conversely, the upregulation of miR-30d in hepato-
cellular carcinoma [31], medulloblastoma [40] and breast
cancer [41] could promote the advanced progression of
patients with these malignancies. Accumulating studies
have identified a variety of target genes for miR-30d in dif-
ferent cancer cells. For example, miR-30d inhibited renal
carcinoma cell proliferation via the regulation of cyclin E2
expression post-transcriptionally [35]; miR-30d enhanced
the invasion and metastasis abilities of hepatocellular car-
cinoma cells by targeting Galphai2 [31]; Ectopic expres-
sion of miR-30d inhibited proliferation and colony
formation of anaplastic thyroid carcinoma cells by indu-
cing G2/M-phase cell-cycle arrest via regulating the Poly-
comb Protein EZH2 [42]. Due to these disparities in
different cancer types, it is necessary to clarify the precise
molecular mechanism underlying the involvement of
miR-30d in various human cancers.
Even though aberrant expression of miR-30d has
been reported in PCa, its associations with cancer
Table 1 Prognostic value of MYPT1 expression for the biochemical recurrence-free, metastasis-free and overall survival in univariate
and multivariate analysis using Cox Regression models
Univariate Multivariate
HR 95% Cl P HR 95% Cl P
Time to BCR
MYPT1 (high vs low) 0.371 0.232–0.593 <0.001 0.468 0.282–0.775 0.003
Tumor stage (T2 vs T3) 1.879 1.207–2.925 0.005 1.123 0.668–1.888 0.661
Surgical margin (+ vs -) 1.805 1.185–2.749 0.006 1.124 0.673–1.876 0.655
Gleason score (<8 vs ≥8) 4.541 2.832–7.280 <0.001 3.482 2.010–6.033 <0.001
Pre-operative PSA (<4 vs ≥4) 1.792 1.090–2.947 0.022 1.941 0.877–4.300 0.102
Age (<66 vs ≥66) 1.502 0.973–2.320 0.067 1.361 0.848–2.183 0.201
Time to Metastasis
MYPT1 (high vs low) 0.376 0.137–1.035 0.058 0.420 0.148–1.191 0.103
Tumor stage (T2 vs T3) 1.574 0.628–3.946 0.333 1.179 0.401–3.464 0.764
Surgical margin (+ vs -) 0.963 0.394–2.356 0.934 0.608 0.208–1.781 0.364
Gleason score (<8 vs ≥8) 4.765 1.945–11.672 0.001 3.563 1.258–10.094 0.017
Pre-operative PSA (<4 vs ≥4) 1.780 0.676–4.684 0.243 0.577 0.202–1.649 0.305
Age (<66 vs ≥66) 0.940 0.361–2.448 0.900 0.744 0.265–2.091 0.575
Time to Death
MYPT1 (high vs low) 0.375 0.183–0.768 0.007 0.334 0.150–0.742 0.007
Tumor stage (T2 vs T3) 1.626 0.852–3.103 0.140 1.305 0.604–2.823 0.498
Surgical margin (+ vs -) 1.178 0.636–2.183 0.603 0.534 0.250–1.142 0.106
Gleason score (<8 vs ≥8) 4.033 2.111–7.705 <0.001 2.941 1.335–6.477 0.007
Pre-operative PSA (<4 vs ≥4) 1.275 0.600–2.713 0.527 1.045 0.388–2.814 0.931
Age (<66 vs ≥66) 1.818 0.980–3.369 0.058 1.876 0.952–3.695 0.069
HR Hazard ratio, CI confidence interval; Surgical margin status, between positive and negative
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progression remain contradictory [11–15]. In the
current study, we identified the upregulation of miR-
30d as a characteristic molecular change in both PCa
cell lines and clinical tissue samples, in line with the
findings of Kobayashi group [11]. Then, we also
confirmed the significant associations of miR-30d up-
regulation with aggressive clinicopathological charac-
teristics, shorter BCR-free and overall survivals of PCa
patients, which prompted us to determine the roles of
miR-30d in malignant phenotypes of PCa in vitro sys-
tems and in vivo models. Our data showed the onco-
genic role of miR-30d through PCa cells viability,
migration, invasion and tube formation assays in vitro,
along with tumor xenografts growth and angiogenesis
in vivo according to both gain-of-function and loss-of-
function experiments. We also found that the pro-
angiogenic effects of miR-30d in PCa might be due to
the upregulation of VEGFA. However, VEGFA was not
a direct target gene of miR-30d according to our
miRNA target gene identification. To elucidate the
mechanisms underlying the regulatory effect of miR-
30d on VEGFA expression in PCa cells, we combined
gene expression profile, three miRNA target predic-
tion algorithms, luciferase report assay, the correlation
analysis in both PCa tissues and cell lines, with both
in vitro and in vivo functional analyses, to confirm
that miR-30d may exert its oncogenic role at least in
part by suppressing MYPT1, which is involved into
the Rho/Rho-kinase pathway [43]. The abnormal of
this pathway may be associated with various
pathological states, such as vascular spasm [44]. There
was an inverse correlation between miR-30d and
MYPT1 mRNA levels in PCa tissues, which was fur-
ther confirmed by evaluating the effects of up- and
down-regulating miR-30d on MYPT1 expression in
PCa cells. In addition, MYPT1 stimulation could
antagonize the effects of miR-30d, implying that
MYPT1 may serve as a downstream mediator of miR-
30d function in PCa. It has been reported that ROK
phosphorylation of threonine 696 on MYPT1 may in-
hibit myosin phosphatase catalytic activity, which can
modulate the motility of cancer and endothelial cells,
and neoangiogenesis [45]. Here, our solid data of both
LNCap and DU145 cells transfected with miR-30d ex-
pressing or si-MYPT1 vectors indicated that miR-30d
upregulation and MYPT1 downregulation significantly
promoted the activation of c-JUN which can bind to
the VEGFA promoter and regulated VEGFA transcrip-
tion directly. These provide further evidence to sup-
port that miR-30d may increase VEGFA expression by
active MYPT1-cJUN pathway (Fig. 6).
Another important finding of this study was that miR-
30d and its direct target gene MYPT1, alone or in com-
bination, were novel independent prognostic markers for
BCR-free survival of patients with PCa. Especially, the
Cox proportional hazards multivariate model based on
the Taylor dataset revealed that the prediction efficiency
of miR-30d/MYPT1 combination to BCR of PCa pa-
tients was stronger than the two markers’ alone. How-
ever, we found that the association between miR-30d
Fig. 5 miR-30d promotes angiogenesis via MYPT1/c-JUN/VEGFA pathway in PCa: a Expression levels of VEGFA protein in LNCaP cells transfected
si-HIF-1α, si-c-JUN, si-AP-2 and si-SP-1 detected by western blot analysis; b ~ f Expression levels of MYPT1, VEGFA, total-c-JUN, p-c-JUN (ser63), p-c-
JUN (ser73) proteins in LNCaP cells transfected with miR-30d expressing or sh-MYPT1 vectors detected by western blot analysis. Data were pre-
sented as Mean ± SD. *P < 0.05. **P < 0.01
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expression and patients' BCR-free survival didn't have
statistical significance based on the TCGA dataset, the
reason for which might be a relative small BCR positive
cohort in this dataset.
Conclusions
Our data offer the promising evidence that miR-30d
may function as an oncogene in human PCa by promot-
ing tumor angiogenesis via regulating MYPT1/c-JUN/
VEGFA pathway signaling. Our results supporting miR-
30d and/or MYPT1 as promising prognostic markers
which have potential implications for allowing clinicians
to screen patients with intensive diseases. Considering
anti-angiogenesis therapy is an important strategy of
cancer treatment, miR-30d might be a novel therapeutic
target for PCa.
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